# Heidelberg Epignostix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/heidelberg-epignostix

- Industry: Biotechnology
- Headquarters: Heidelberg, Germany
- Website: www.epignostix.com/
- Total disclosed funding: $4.6M
- Latest round: Seed (Jun 20, 2024)
- Investors on record: 4

## About

Founded in 2022 and based in Heidelberg, Germany, Heidelberg Epignostix GmbH operates as a biotechnology company that uses technology to develop cancer patients' diagnostics. In July 2024, Heidelberg Epignostix GmbH raised EUR 4.3 million in seed funding from investors. As of 2024, the company is led by its CEO, David T. W. Jones.

The company specializes in the research and development, certification, and marketing of software solutions designed for molecular tumor classification. These solutions utilize DNA methylation profiling and advanced machine learning algorithms to achieve precise and accurate cancer diagnosis. The firm’s core offering is its technology in DNA methylation analysis. This technology enables the classification of tumors at a molecular level, providing critical insights that can inform personalized treatment plans. In addition, Heidelberg’s pipeline also includes sarcoma classifiers, more classifiers, and nanopore classifiers, which are under development and will offer tailored treatment strategies and improved patient outcomes.

The organization plans to use the July 2024 funding to drive market development for its primary indication for brain tumor classification.

## Funding rounds

- Seed, Jun 20, 2024, $4.6M — LBBW Venture Capital, High-Tech Gruenderfonds, MBG Baden-Wuerttemberg, CARMA FUND Management

## Investors

- LBBW Venture Capital (https://capitalatlas.ai/funds/lbbw-venture-capital) — Seed
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- MBG Baden-Wuerttemberg (https://capitalatlas.ai/funds/mbg-baden-wuerttemberg) — Seed
- CARMA FUND Management (https://capitalatlas.ai/funds/carma-fund-management) — Seed